Endothelial dysfunction in patients with angina and non-obstructed coronary arteries is associated with an increased risk of mayor cardiovascular events. Results of the Spanish ENDOCOR registry.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Jan 2023
Historique:
received: 30 06 2022
revised: 16 10 2022
accepted: 28 10 2022
pubmed: 4 11 2022
medline: 15 12 2022
entrez: 3 11 2022
Statut: ppublish

Résumé

Coronary endothelial dysfunction and vasospasm are potential causes of ischemia in patients without obstructive coronary stenoses (INOCA). To evaluate the prevalence of endothelial dysfunction and the clinical profile of patients with INOCA in Spain, as well as to identify the predictors and the prognostic impact of endothelial dysfunction in this scenario. A total of 438 consecutive patients with INOCA in whom the acetylcholine test was performed were prospectively enrolled. Patients were followed up at 1 and 2 years. Mean age was 62 ± 11 years with 60% female. Clinical presentation comprised 52.6% angina at rest, 61.2% exertional angina, and 31.7% dyspnea. There were no major complications of the acetylcholine test. Endothelial dysfunction was observed in 198 (45%) of patients, with severe vasoconstriction (defined as over 70% constriction), being observed in 101 (23%). Multivariable regression analysis showed that endothelial dysfunction was predicted by the presence of exertional angina (OR 2.2; CI95%1.01-2.55; p = 0.02), prior coronary disease (OR 2.46; CI95% 1.57-3.89; p < 0.01), and coronary intramyocardial bridging (2.35; CI95% 1.02-5.60; p = 0.04). Patients with endothelial dysfunction presented with worsening angina compared to those without endothelial dysfunction (25.6% vs. 12.8%) and also presented with increased levels of minimal effort angina (40% vs. 26,7%, p = 0.03) more frequently during the follow up than those without endothelial dysfunction. Endothelial dysfunction was also an independent predictor of the occurrence of myocardial infarction or unstable angina at one year (OR 2.85, CI 95% 1.01-9.25; p = 0.03). Endothelial dysfunction is present in almost half of patients with INOCA and is associated with worsening symptoms, as well as with a higher rate of adverse events.

Sections du résumé

BACKGROUND BACKGROUND
Coronary endothelial dysfunction and vasospasm are potential causes of ischemia in patients without obstructive coronary stenoses (INOCA).
OBJECTIVE OBJECTIVE
To evaluate the prevalence of endothelial dysfunction and the clinical profile of patients with INOCA in Spain, as well as to identify the predictors and the prognostic impact of endothelial dysfunction in this scenario.
METHODS METHODS
A total of 438 consecutive patients with INOCA in whom the acetylcholine test was performed were prospectively enrolled. Patients were followed up at 1 and 2 years.
RESULTS RESULTS
Mean age was 62 ± 11 years with 60% female. Clinical presentation comprised 52.6% angina at rest, 61.2% exertional angina, and 31.7% dyspnea. There were no major complications of the acetylcholine test. Endothelial dysfunction was observed in 198 (45%) of patients, with severe vasoconstriction (defined as over 70% constriction), being observed in 101 (23%). Multivariable regression analysis showed that endothelial dysfunction was predicted by the presence of exertional angina (OR 2.2; CI95%1.01-2.55; p = 0.02), prior coronary disease (OR 2.46; CI95% 1.57-3.89; p < 0.01), and coronary intramyocardial bridging (2.35; CI95% 1.02-5.60; p = 0.04). Patients with endothelial dysfunction presented with worsening angina compared to those without endothelial dysfunction (25.6% vs. 12.8%) and also presented with increased levels of minimal effort angina (40% vs. 26,7%, p = 0.03) more frequently during the follow up than those without endothelial dysfunction. Endothelial dysfunction was also an independent predictor of the occurrence of myocardial infarction or unstable angina at one year (OR 2.85, CI 95% 1.01-9.25; p = 0.03).
CONCLUSIONS CONCLUSIONS
Endothelial dysfunction is present in almost half of patients with INOCA and is associated with worsening symptoms, as well as with a higher rate of adverse events.

Identifiants

pubmed: 36328111
pii: S0167-5273(22)01680-1
doi: 10.1016/j.ijcard.2022.10.169
pii:
doi:

Substances chimiques

Acetylcholine N9YNS0M02X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-25

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Lilian Grigorian-Shamagian (L)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

Juan Francisco Oteo (JF)

Hospital Universitario de Puerta de Hierro, Spain.

Alejandro Gutiérrez-Barrios (A)

Hospital Universitario Puerta del Mar de Cádiz, Spain.

Omar Abdul-Jawad Altisent (O)

Hospital German Trías i Pujol, Badalona, Spain.

Ignacio Amat-Santos (I)

Departamento de Cardiología, Hospital Clínico Universitario, Valladolid, Spain.

Agustín Fernández Cisnal (AF)

Hospital Clínico Universitario de Valencia, Spain.

Jessica Roa (J)

Hospital Juan Ramón Jiménez de Huelva, Spain.

Carlos Arellano Serrano (C)

Hospital Universitario de Puerta de Hierro, Spain.

Edgar Fadeuilhe (E)

Hospital German Trías i Pujol, Badalona, Spain.

Carlos Cortés (C)

Departamento de Cardiología, Hospital Clínico Universitario, Valladolid, Spain.

Ricardo Sanz-Ruiz (R)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

María Eugenia Vázquez-Alvarez (ME)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

Felipe Díez Delhoyo (F)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

María Tamargo (M)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

Javier Soriano (J)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

Jaime Elízaga (J)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

Francisco Fernández-Avilés (F)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain.

Enrique Gutiérrez (E)

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain; Universidad Complutense de Madrid, Spain; Centro de investigación biomédica en red - Enfermedades cardiovasculares (CIBERCV, Instituto de Salud Carlos III, Madrid), Spain. Electronic address: enrique.gutierrez@salud.madrid.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH